Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of ...

Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...

Image source: The Motley Fool. Need a quote from one of our analysts? Email pr@fool.com Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. A $77.2 ...

Simulations Plus, Inc. (SLP) reported third-quarter fiscal 2025 adjusted earnings of 45 cents per share, which expanded 66.7% year over year. The figure also surpassed the Zacks Consensus Estimate of ...

Simulations Plus, Inc.SLP was a big mover last session, as the company saw its shares rise nearly 6% on the day. Shares gained after the company reported higher earnings and revenues for the third ...

Simulations Plus faces soft revenue growth in the short term, due largely to macro conditions. The negatives appear to have been priced in, though, after a period of significant share price declines.

Simulations Plus SLP recently announced the acquisition of Pro-ficiency Holdings, Inc. and its subsidiaries from QHP Capital and its minority shareholders. The company specializes in offering ...

On Wednesday, 10 September 2025, Simulations Plus (NASDAQ:SLP) presented at the Morgan Stanley 23rd Annual Global Healthcare Conference, celebrating its 30th anniversary. CEO Sean O’Connor highlighted ...

Harding Loevner, an investment management firm, published its “Global Small Companies Equity Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. A quarterly net return ...